These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2325 related items for PubMed ID: 20110032

  • 1. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D, Park HJ, Ko SK.
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP, Visseren FL, de Wit GA, Algra A.
    BMJ; 2011 Mar 30; 342():d1672. PubMed ID: 21450800
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA.
    Can J Cardiol; 2005 Jun 30; 21(8):681-7. PubMed ID: 16003451
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF, Heeg BM, Herlitz J, van Hout BA.
    Appl Health Econ Health Policy; 2010 Jun 30; 8(4):251-65. PubMed ID: 20578780
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
    Ohsfeldt RL, Olsson AG, Jensen MM, Gandhi SK, Paulsson T.
    J Med Econ; 2012 Jun 30; 15(1):125-33. PubMed ID: 22050473
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA.
    JAMA; 2015 Jul 14; 314(2):142-50. PubMed ID: 26172894
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group.
    Clin Ther; 2006 Mar 14; 28(3):432-44. PubMed ID: 16750458
    [Abstract] [Full Text] [Related]

  • 19. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F, Blackhouse G, Assasi N, Campbell K, Levin M, Bowen J, Tarride JE, Pi D, Goeree R.
    Clin Ther; 2009 May 14; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.
    Clin Ther; 2008 Jan 14; 30(1):195-205. PubMed ID: 18343257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 117.